eF-site ID 3iwm-ABCD PDB Code 3iwm Chain A, B, C, D click to enlarge Title The octameric SARS-CoV main protease Classification HYDROLASE Compound 3C-like proteinase Source Human SARS coronavirus (SARS-CoV) (Severe acute respiratory syndrome coronavirus) (3IWM) Sequence A:  SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPR HVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGH SMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNG SPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFC YMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTI TLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE PLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRT ILGSTILEDEFTPFDVVRQCS B:  SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPR HVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGH SMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNG SPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFC YMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTI TLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE PLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRT ILGSTILEDEFTPFDVVRQCS C:  SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPR HVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGH SMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNG SPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFC YMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTI TLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE PLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRT ILGSTILEDEFTPFDVVRQC D:  SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPR HVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGH SMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNG SPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFC YMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTI TLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE PLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRT ILGSTILEDEFTPFDVVRQC Description Functional site 1) chain A residue 25 type sequence T description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 2) chain A residue 26 type sequence T description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 3) chain A residue 27 type sequence L description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 4) chain A residue 41 type sequence H description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 5) chain A residue 140 type sequence F description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 6) chain A residue 141 type sequence L description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 7) chain A residue 142 type sequence N description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 8) chain A residue 143 type sequence G description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 9) chain A residue 145 type sequence C description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 10) chain A residue 163 type sequence H description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 11) chain A residue 164 type sequence H description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 12) chain A residue 165 type sequence M description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 13) chain A residue 166 type sequence E description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 14) chain A residue 168 type sequence P description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 15) chain A residue 187 type sequence D description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 16) chain A residue 188 type sequence R description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 17) chain A residue 189 type sequence Q description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 18) chain A residue 190 type sequence T description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 19) chain A residue 191 type sequence A description BINDING SITE FOR CHAIN H OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC1 20) chain B residue 25 type sequence T description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 21) chain B residue 41 type sequence H description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 22) chain B residue 140 type sequence F description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 23) chain B residue 142 type sequence N description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 24) chain B residue 143 type sequence G description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 25) chain B residue 145 type sequence C description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 26) chain B residue 163 type sequence H description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 27) chain B residue 164 type sequence H description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 28) chain B residue 165 type sequence M description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 29) chain B residue 166 type sequence E description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 30) chain B residue 168 type sequence P description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 31) chain B residue 189 type sequence Q description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 32) chain B residue 190 type sequence T description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 33) chain B residue 192 type sequence Q description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 34) chain C residue 24 type sequence T description BINDING SITE FOR CHAIN F OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC2 35) chain B residue 24 type sequence T description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 36) chain C residue 27 type sequence L description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 37) chain C residue 41 type sequence H description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 38) chain C residue 49 type sequence M description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 39) chain C residue 140 type sequence F description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 40) chain C residue 142 type sequence N description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 41) chain C residue 143 type sequence G description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 42) chain C residue 145 type sequence C description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 43) chain C residue 163 type sequence H description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 44) chain C residue 164 type sequence H description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 45) chain C residue 165 type sequence M description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 46) chain C residue 166 type sequence E description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 47) chain C residue 167 type sequence L description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 48) chain C residue 168 type sequence P description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 49) chain C residue 188 type sequence R description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 50) chain C residue 189 type sequence Q description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 51) chain C residue 190 type sequence T description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 52) chain C residue 191 type sequence A description BINDING SITE FOR CHAIN G OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC3 53) chain D residue 26 type sequence T description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 54) chain D residue 41 type sequence H description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 55) chain D residue 140 type sequence F description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 56) chain D residue 141 type sequence L description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 57) chain D residue 142 type sequence N description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 58) chain D residue 143 type sequence G description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 59) chain D residue 145 type sequence C description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 60) chain D residue 163 type sequence H description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 61) chain D residue 164 type sequence H description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 62) chain D residue 165 type sequence M description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 63) chain D residue 166 type sequence E description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 64) chain D residue 167 type sequence L description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 65) chain D residue 168 type sequence P description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 66) chain D residue 187 type sequence D description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 67) chain D residue 188 type sequence R description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 68) chain D residue 189 type sequence Q description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 69) chain D residue 190 type sequence T description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 70) chain D residue 191 type sequence A description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 71) chain D residue 192 type sequence Q description BINDING SITE FOR CHAIN E OF N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~- ((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3- YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE source : AC4 72) chain A residue 41 type catalytic sequence H description 830 source MCSA : MCSA1 73) chain A residue 143 type catalytic sequence G description 830 source MCSA : MCSA1 74) chain A residue 145 type catalytic sequence C description 830 source MCSA : MCSA1 75) chain B residue 41 type catalytic sequence H description 830 source MCSA : MCSA2 76) chain B residue 143 type catalytic sequence G description 830 source MCSA : MCSA2 77) chain B residue 145 type catalytic sequence C description 830 source MCSA : MCSA2 78) chain C residue 41 type catalytic sequence H description 830 source MCSA : MCSA3 79) chain C residue 143 type catalytic sequence G description 830 source MCSA : MCSA3 80) chain C residue 145 type catalytic sequence C description 830 source MCSA : MCSA3 81) chain D residue 41 type catalytic sequence H description 830 source MCSA : MCSA4 82) chain D residue 143 type catalytic sequence G description 830 source MCSA : MCSA4 83) chain D residue 145 type catalytic sequence C description 830 source MCSA : MCSA4 84) chain A residue 41 type ACT_SITE sequence H description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1 85) chain A residue 145 type ACT_SITE sequence C description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1 86) chain B residue 41 type ACT_SITE sequence H description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1 87) chain B residue 145 type ACT_SITE sequence C description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1 88) chain C residue 41 type ACT_SITE sequence H description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1 89) chain C residue 145 type ACT_SITE sequence C description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1 90) chain D residue 41 type ACT_SITE sequence H description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1 91) chain D residue 145 type ACT_SITE sequence C description For 3CL-PRO activity => ECO:0000255|PROSITE-ProRule:PRU00772 source Swiss-Prot : SWS_FT_FI1

Display surface Download Links